Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Metolazone
Drug ID BADD_D01444
Description A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.
Indications and Usage For the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.
Marketing Status approved
ATC Code C03BA08
DrugBank ID DB00524
KEGG ID D00431
MeSH ID D008788
PubChem ID 4170
TTD Drug ID D01WLC
NDC Product Code 64330-115; 46708-532; 51407-431; 51407-432; 0527-2217; 72888-053; 72888-054; 76385-136; 10135-765; 50742-351; 51079-023; 60687-624; 62332-532; 71406-113; 71406-115; 65392-2201; 0185-0055; 51079-024; 63629-7875; 0527-2215; 71335-1944; 72888-052; 69575-4023; 60687-635; 0378-6172; 69292-562; 0527-2216; 71406-114; 46708-534; 63629-8733; 71610-285; 76385-137; 43353-999; 0185-5050; 62332-534; 69292-564; 69292-566; 69766-067; 0185-5600; 50742-350; 51407-433; 63629-8722; 0378-6173; 0904-6916; 17381-254; 0904-7138; 10135-767; 43353-931; 50742-349; 62332-533; 0378-6174; 71610-142; 76385-138; 43353-890; 0904-7139; 10135-766; 46708-533
UNII TZ7V40X7VX
Synonyms Metolazone | Microx | Mykrox | Zaroxolyn | Diulo | SR-720-22 | SR 720 22 | SR72022
Chemical Information
Molecular Formula C16H16ClN3O3S
CAS Registry Number 17560-51-9
SMILES CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Urticaria23.04.02.001; 10.01.06.001--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vasculitis necrotising24.12.04.029; 10.02.02.008--Not Available
Venous thrombosis24.01.01.008--Not Available
Ventricular tachycardia02.03.04.0100.000770%
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Eye pruritus06.04.05.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Major depression19.15.01.003--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Ill-defined disorder08.01.03.049--Not Available
Chronic kidney disease20.01.03.0170.000700%
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Acute kidney injury20.01.03.0160.001576%
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.0210.000876%Not Available
The 4th Page    First    Pre   4    Total 4 Pages